業內動態
cGMP制藥潔凈室整體解決方案:細胞治療產品、單克隆抗體、疫苗以及口服固體抗病毒藥物的生產
發布時間:2022-04-08 17:23:12
● ● 齊 心 協 力 | 共 渡 難 關 ● ●
目前,全球仍在繼續競相尋找抗擊COVID-19 爆發流行的最有效策略。迫切需要有效的公共衛生干預措施和可靠的治療手段來扭轉這一激增趨勢,與此同時也推動了多種用于改善患者預后的藥物開發。
感染早期進行治療是最有希望的,在尋找早期重要的臨床數據過程中,發現當前批準的藥物有新的適應癥(又稱藥物再利用)?;谶@個情況,把早期治療中,對人體安全有效的藥物分子進行聯合用藥,用于各種篩選試驗。據說這是一種具有成本效益的藥物開發技術,相比新療法可以更快地治療新冠肺炎患者。
人類與COVID-19的斗爭仍在繼續,從長遠角度來看,接種新冠疫苗是最有效的預防手段,它有助于個體產生免疫力,在不良事件發生時使個人感染風險降到最低。疫苗是一種生物物質,在外來入侵物質(如病毒)刺激身體后做出應答并產生抗體??贵w是由免疫B細胞天然產生的蛋白質,其主要機制是通過與病毒部分特異性結合并阻止其進入細胞,從而免于感染或者控制感染發展為疾病。大多數獲得批準的疫苗基本是通過皮下注射和肌肉注射這兩種方式進行接種。
通常,這些抗體在接種疫苗或感染后自然產生,但也可以在實驗室中通過生物工程進行制備。實驗室制備的抗體稱為單克隆抗體 (mAb),其產生的方式主要通過靜脈注射以及注射給藥。
盡管最近全球疫情有所改善,但許多國家仍面臨著早期治療需求無法滿足的困境,早期檢測對于避免產生重癥病例和免于住院治療具有重要意義。因此,隨著治療方法的不斷研究,抗病毒的口服固體制劑(OSD)出現并應用。第一個用于早期COVID-19治療的抗病毒口服藥物是由默克公司研發的莫努匹韋,臨床數據表明,在治療初期或病毒仍在復制的階段,該藥品具有很高的治療療效,這種藥物會增加病毒RNA突變的頻率并削弱病毒復制。
參考文獻:
1. Brande, D., Milholland, D., & Haycocks, N. (2017). Why is 90 FPM Considered Standard for Cleanroom Airflow?. ISPE. Retrieved from: https://ispe.org/pharmaceutical-engineering/march-april-2017/why-90-fpm-considered-standard-cleanroom-airflow
2. Channel News Asia (2021). Merck COVID-19 pill sparks calls for access for lower income countries. Retrieved from: https://www.channelnewsasia.com/world/merck-covid-19-pill-sparks-calls-access-lower-income-countries-2250266
3. COVID-19 Prevention Network. (n.d.). The Science of COVID-19 Vaccines and Antibodies. Retrieved from: https://www.coronaviruspreventionnetwork.org/coronavirus-vaccine-and-antibody-science/
4. Cumbers, John (2020). Timeline Shows 3 Paths To COVID-19 Treatment And Prevention (Infographics). Forbes. Retrieved from: https://www.forbes.com/sites/johncumbers/2020/03/25/timeline-shows-3-paths-to-COVID-19-treatment-and-prevention-infographic/?sh=25e975ad4789
5. Institute of Environmental Sciences and Technology. (2001). FED-STD-209E. Retrieved from: https://www.iest.org/Standards-RPs/ISO-Standards/FED-STD-209E
6. International Organization for Standardization. (2015). ISO 14644-1:2015, Cleanrooms and associated environments - Part 1: Classification of air cleanliness by particle concentration (2nd ed.). ISO 2015.
7. Naughton, P. (2019). History of Cleanrooms. ASHRAE Journal. Retrieved from: https://www.ashrae.org/file%20library/technical%20resources/ashrae%20journal/125thanniversaryarticles/38-54_naughton_historical_v2.pdf
8. Ramirez, J., Sharpe, L., & Peppas, N. (2017). Current state and challenges in developing oral vaccines. Advanced Drug Delivery Reviews, 114, 116-131. Retrieved from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6132247/
9. U.S. Department of Health and Human Services. (2004). Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing — Current Good Manufacturing Practice. Food and Drug Administration. Retrieved from: https://www.fda.gov/media/71026/download
10. Vaccines Europe. (2020). How are vaccines produced? Retrieved from: https://www.vaccineseurope.eu/about-vaccines/how-are-vaccines-produced
圖文crESCO生命科學、網絡
- E N D -